| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 10801,039
- Publication Date: October 13, 2020
- Appl. No: 13/917259
- Application Filed: June 13, 2013
- Assignees: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (Glasgow, GB), Boehringer Ingelheim Animal Health USA Inc. (Duluth, GA, US)
- Claim: 1. An immunogenic or vaccine composition comprising a recombinant Bluetongue Virus (BTV) vector comprising a vector backbone derived from a BTV-1 genome and a polynucleotide encoding a BTV-8 VP2 polypeptide and not a polynucleotide encoding a BTV-8 VP5 polypeptide.
- Claim: 2. A recombinant BTV vector comprising a vector backbone derived from a BTV-1 genome and a polynucleotide encoding a BTV-8 VP2 polypeptide and not a polynucleotide encoding a BTV-8 VP5 polypeptide.
- Claim: 3. A method of producing a recombinant BTV vector comprising transfecting a cell with RNAs encoding VP2 of BTV-8 and not a polynucleotide encoding a BTV-8 VP5 polypeptide; and RNAs encoding VP1, VP3, VP4, VP7, NS1, NS2, VP6NS4, and NS3/3A of BTV-1.
- Claim: 4. A method of vaccinating an animal comprising: administering to the animal the immunogenic or vaccine composition according to claim 1 .
- Claim: 5. The method of claim 4 , wherein the immunogenic or vaccine composition is administered as part of a prime-boost regimen.
- Claim: 6. A method for inducing an immunogenic or protective response in an animal against one or more pathogens comprising: administering to the animal the immunogenic or vaccine composition according to claim 1 .
- Claim: 7. The method of claim 6 , wherein the animal is a bovine, ovine, caprine, or equine.
- Patent References Cited: WO2009068870 June 2009
- Other References: Anderson G. A., J. L. Stott, et al. (1985). “Subclinical and clinical bluetongue disease in cattle: clinical, pathological and pathogenic considerations.” Prog Clin Biol Res 178: 103-7. cited by applicant ; Andrew, M., P. Whiteley, et al. (1995). “Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus.” Vet Immunol Immunopathol 47(3-4): 311-22. cited by applicant ; Athmaram, T. N., G. Bali, et al. (2007). “Heterologous expression of Bluetongue VP2 viral protein fragment in Pichia pastoris.” Virus genes 35(2): 265-271. cited by applicant ; Bonneau, K. R., B. A. Mullens, et al. (2001). “Occurrence of genetic drift and founder effect during quasispecies evolution of the VP2 and NS3/NS3A genes of bluetongue virus upon passage between sheep, cattle, and Culicoides sonorensis.” J Virol 75(17): 8298-305. cited by applicant ; Boone, J. D., U. B. Balasuriya, et al. (2007). “Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.” Vaccine 25(4): 672-678. cited by applicant ; Boyce, M., C. C. Celma, et al. (2008). “Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts.” Journal of virology 82(17): 8339-8348. cited by applicant ; Breard, E., G. Belbis, et al. (2011). “Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats.” Vaccine 29(13): 2495-2502. cited by applicant ; Calvo-Pinilla, E., T. Rodriguez-Calvo, et al. (2009). “Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(−/−) mice against lethal bluetongue infection.” Vaccine 28(2): 437-445. cited by applicant ; Capocefalo, A., V. Franceschi, et al. (2010). “Expression and secretion of Bluetongue virus serotype 8 (BTV-8)VP2 outer capsid protein by mammalian cells.” Journal of virological methods 169(2): 420-424. cited by applicant ; Cowley, J. A. and B. M. Gorman (1989). “Cross-neutralization of genetic reassortants of bluetongue virus serotypes 20 and 21.” Veterinary microbiology 19(1): 37-51. cited by applicant ; De Mattos, C. A., C. C. de Mattos, et al. (1994). “Heterogeneity of the L2 gene of field isolates of bluetongue virus serotype 17 from the San Joaquin Valley of California.” Virus Res 31(1): 67-87. cited by applicant ; DeMaula, C. D., K. R. Bonneau, et al. (2000). “Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies.” Virus Res 67(1): 59-66. cited by applicant ; Di Plessis M. et al. 1998,“Protein aggregation complicates the development of baculovirus-expressed African horsesickness virus serotype 5 VP2 subunit vaccines”, Onderstepoort Journal of Veterinary Research 65: 321-329. cited by applicant ; Eschbaumer, M., B. Hoffmann, et al. (2009). “Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.” Vaccine 27(31): 4169-4175. cited by applicant ; Forzan, M., C. Wirblich, et al. (2004). “A capsid protein of nonenveloped Bluetongue virus exhibits membrane fusion activity.” Proceedings of the National Academy of Sciences of the United States of America 101(7): 2100-2105. cited by applicant ; Franceschi, V., A. Capocefalo, et al. (2011). “Immunization of knock-out alpha/beta interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen.” Vaccine 29(16): 3074-3082. cited by applicant ; Fukusho, A., G. D. Ritter, et al. (1987). “Variation in the bluetongue virus neutralization protein VP2.” The Journal of general virology 68 ( Pt 11): 2967-2973. cited by applicant ; Ghiasi, H., A. Fukusho, et al. (1987). “Identification and characterization of conserved and variable regions in the neutralization VP2 gene of bluetongue virus.” Virology 160(1): 100-109. cited by applicant ; Gould, A. R. and B. T. Eaton (1990). “The amino acid sequence of the outer coat protein VP2 of neutralizing monoclonal antibody-resistant, virulent and attenuated bluetongue viruses.” Virus research 17(3): 161-172. cited by applicant ; Grubman, M.J. & Lewis, S.A., Identification and characterization of the structural and nonstructural proteins of African horsesickness virus and determination of the genome coding assignments (1992). Virology 186, 444-451. cited by applicant ; Hamers, C., S. Galleau, et al. (2009). “Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle.” The Veterinary record 165(13): 369-373. cited by applicant ; Hassan, S. S. and P. Roy (1999). “Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry.” J Virol 73(12): 9832-42. cited by applicant ; Hofmann, M. A., S. Renzullo, et al. (2008). “Genetic characterization of toggenburg orbovirus, a new bluetongue virus, from goats, Switzerland.” Emerging infectious diseases 14(12): 1855-1861. cited by applicant ; Huismans, H. and B. J. Erasmus (1981). “Identification of the serotype-specific and group-specific antigens of bluetongue virus.” Onderstepoort J Vet Res 48(2): 51-8. cited by applicant ; Huismans, H., N. T. van der Walt, et al. (1987). “Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep.” Virology 157(1): 172-9. cited by applicant ; Hund, A., N. Gollnick, et al. (2012). “A two year BTV-8 vaccination follow up: molecular diagnostics and assessment of humoral and cellular Immune reactions.” Veterinary microbiology 154(3-4): 247-256. cited by applicant ; Hwang, G. Y. and J. K. Li (1993). “Identification and localization of a serotypic neutralization determinant on the VP2 protein of bluetongue virus 13.” Virology 195(2): 859-862. cited by applicant ; Inumaru, S. and P. Roy (1987). “Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector.” Virology 157(2): 472-479. cited by applicant ; Jewell, J. E. and J. O. Mecham (1994). “Identification of an amino acid on VP2 that affects neutralization of bluetongue virus serotype 10.” Virus research 33(2): 139-144. cited by applicant ; Lewis, S.A. and Grubman, M.J., VP2 is the major exposed protein on orbiviruses (1991). Archives of Virology 121, 233-236. cited by applicant ; Lobato, Z. I., B. E. Coupar, et al. (1997). “Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.” Vet Immunol Immunopathol 59(3-4): 293-309. cited by applicant ; Lourenco, S. and P. Roy (2011). “In vitro reconstitution of Bluetongue virus infectious cores.” Proceedings of the National Academy of Sciences of the United States of America 108(33): 13746-13751. cited by applicant ; Maan, S., N. S. Maan, et al. (2007). “Analysis and phylogenetic comparisons of full-length VP2 genes of the 24 bluetongue virus serotypes.” The Journal of general virology 88(Pt 2): 621-630. cited by applicant ; Maan, S., N. S. Maan, et al. (2011). “Complete genome characterisation of a novel 26th bluetongue virus serotype from Kuwait.” PloS one 6(10): e26147. cited by applicant ; MacLachlan, N. J. (1994). “The pathogenesis and immunology of bluetongue virus infection of ruminants.” Comp Immunol Microbiol Infect Dis 17(3-4): 197-206. cited by applicant ; Matsuo, E., C. C. Celma, et al. (2011). “Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge.” Journal of virology 85(19): 10213-10221. cited by applicant ; Mertens, P. P., S. Pedley, et al. (1989). “Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype.” Virology 170(2): 561-565. cited by applicant ; Minke, J.M., Audonnet, J.C., Fischer, L., Equine viral vaccines: the past, present and future (2004b). Veterinary Research 35: 425-443. cited by applicant ; Minke, J.M., Siger, L., Karaca, K., Austgen, L., Gordy, P., Bowen, R., Renshaw, R.W., Loosmore, S., Audonnet, J.C., Nordgren, B., Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge (2004a). Arch. Virol. Suppl. 221-230. cited by applicant ; Minke, J.M., Toulemonde, C.E., Couple, H., Guigal, P.M., Dinic, S., Sindle, T., Jessett, D., Black, L., Bublot, M., Pardo, M.C., Audonnet, J.C., Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N3 virus in the protection of ponies from viral challenge (2007). American Journal of Veterinary Research 68: 213-219. cited by applicant ; Palmarini M et al., PloS pathogens, 2011, 7(12): e1002477. cited by applicant ; Pearson, L.D., Roy, P., Genetically engineered multi-component virus-like particles as veterinary vaccines (1993). Immunol.Cell Biol. 71 ( Pt 5), 381-389. cited by applicant ; Perez de Diego, A. C., P. J. Sanchez-Cordon, et al. (2012). “Characterization of the immune response induced by a commercially available inactivated bluetongue virus serotype 1 vaccine in sheep.” TheScientificWorldJournal 2012: 147158. cited by applicant ; Perrin, A., E. Albina, et al. (2007). “Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants.” Vaccine 25(37-38): 6774-6783. cited by applicant ; Piet A van Rijn et al., Virology Journal, 2010, 7:261. cited by applicant ; Poulet, H., Brunet, S., Boularand, C., Guiot, A.L., Leroy, V., Tartaglia, J., Minke, J., Audonnet, J.C., Desmettre, P., Efficacy of a canarypox virus-vectored vaccine against feline leukaemia (2003). Veterinary Record 153: 141-145. cited by applicant ; Pritchard, L. I. and A. R. Gould (1995). “Phylogenetic comparison of the serotype-specific VP2 protein of bluetongue and related orbiviruses.” Virus research 39(2-3): 207-220. cited by applicant ; Roy et al., Journal of Viology, 2011, 85, 19;10213-10221. cited by applicant ; Roy, P. (1996). “Orbivirus structure and assembly.” Virology 216(1): 1-11. cited by applicant ; Roy, P., T. Urakawa, et al. (1990). “Recombinant virus vaccine for bluetongue disease in sheep.” J Virol 64(5): 1998-2003. cited by applicant ; Scanlen, M., Paweska, J.T., Verschoor, J.A., Van Dijk, A.A., The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant (2002). Vaccine 20, 1079-1088. cited by applicant ; Schwartz-Cornil, I., P. P. Mertens, et al. (2008). “Bluetongue virus: virology, pathogenesis and immunity.” Veterinary research 39(5): 46. cited by applicant ; Spreull, J. (1905). “Malarial catarrhal fever (bluetongue) of sheep in South Africa.” J. Comp. Path.. Ther. 18: 321-337. cited by applicant ; Stewart, M., C. I. Dovas, et al. (2012). “Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.” Vaccine 30(12): 2131-2139. cited by applicant ; Van Gennip, R. G., D. Veldman, et al. (2010). “Genetic modification of Bluetongue virus by uptake of “synthetic” genome segments.” Virology journal 7: 261. cited by applicant ; Van Gennip, R. G., S. G. van de Water, et al. (2012). “Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.” PloS one 7(9): e44619. cited by applicant ; Van Gennip, R. G., S. G. van de Water, et al. (2012). “Rescue of recent virulent and avirulent field strains of bluetongue virus by reverse genetics.” PloS one 7(2): e30540. cited by applicant ; Verwoerd, D. W., H. J. Els, et al. (1972). “Structure of the bluetongue virus capsid.” J Virol 10 (4) :783-94. cited by applicant ; Wei, P., E. C. Sun, et al. (2013). “Identification of a novel bluetongue virus 1-specific B-cell epitope using a monoclonal antibody against the VP2 protein.” Archives of virology 158(5): 1099-1104. cited by applicant ; White, D. M., W. C. Wilson, et al. (2005). “Studies on overwintering of bluetongue viruses in insects.” J Gen Virol 86(Pt 2): 453-62. cited by applicant ; Wilson, W. C. and J. O. Mecham (2000) . “Molecular Evolution of Orbiviruses . ” Proc USAHA 104: 169-180. cited by applicant ; Zhang, X., M. Boyce, et al. (2010) . “Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins.” Proceedings of the National Academy of Sciences of the United States of America 107(14): 6292-6297. cited by applicant
- Primary Examiner: Horning, Michelle S
- Attorney, Agent or Firm: Ezcurra, John ; Shope, Suzanne Seavello
|
